Top

05-02-2024 | Metastasis | Review

Interrogating the roles of lymph node metastasis in systemic immune surveillance

Authors: Pamela A. Basto, Nathan E. Reticker-Flynn

Published in: Clinical & Experimental Metastasis

Abstract

Lymph nodes (LNs) are principal orchestrators of the adaptive immune response, yet in the context of malignancy, they are typically the first sites of metastasis. When tumors spread to LNs, they alter the immune repertoire, ultimately reconditioning it in a manner that suppresses anti-tumor immunity and promotes further metastatic dissemination. Conversely, activation of anti-tumor immunity within LNs is essential for immunotherapy, suggesting clinical approaches to radiotherapy in LNs and lymphadenectomy may need to be reconsidered in the context of immune checkpoint blockade (ICB). Herein, we discuss our understanding of the immune remodeling that coincides with LN metastasis as well as recent clinical studies exploring neoadjuvant immunotherapy and the roles of LNs in treatment of solid organ malignancies.

Hutchinson L, Kirk R (2011) New paradigms to explain metastasis. Nat Rev Clin Oncol 8(6):313. https://doi.org/10.1038/nrclinonc.2011.68CrossRefPubMed

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF (2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 24(5):541–550. https://doi.org/10.1038/s41591-018-0014-xCrossRefPubMedPubMedCentral

Hebert JD, Neal JW, Winslow MM (2023) Dissecting metastasis using preclinical models and methods. Nat Rev Cancer 23(6):391–407. https://doi.org/10.1038/s41568-023-00568-4CrossRefPubMed

Amin MBE, S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR (2017) AJCC Cancer Staging Manual, 8th edn. Springer: American Joint Commission on Cancer

von Andrian UH, Mempel TR (2003) Homing and cellular traffic in lymph nodes. Nat Rev Immunol 3(11):867–878. https://doi.org/10.1038/nri1222CrossRef

Chandra P, Grigsby SJ, Philips JA (2022) Immune evasion and provocation by Mycobacterium tuberculosis. Nat Rev Microbiol 20(12):750–766. https://doi.org/10.1038/s41579-022-00763-4CrossRefPubMedPubMedCentral

Ganchua SKC, White AG, Klein EC, Flynn JL (2020) Lymph nodes—the neglected battlefield in tuberculosis. PLoS Pathog 16(8):e1008632. https://doi.org/10.1371/journal.ppat.1008632CrossRefPubMedPubMedCentral

Swartz MA, Lund AW (2012) Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer 12(3):210–219. https://doi.org/10.1038/nrc3186CrossRefPubMed

Steele MM, Jaiswal A, Delclaux I, Dryg ID, Murugan D, Femel J, Son S, du Bois H, Hill C, Leachman SA, Chang YH, Coussens LM, Anandasabapathy N, Lund AW (2023) T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control. Nat Immunol 24(4):664–675. https://doi.org/10.1038/s41590-023-01443-yCrossRefPubMed

10.

Leong SP, Pissas A, Scarato M, Gallon F, Pissas MH, Amore M, Wu M, Faries MB, Lund AW (2022) The lymphatic system and sentinel lymph nodes: conduit for cancer metastasis. Clin Exp Metastasis 39(1):139–157. https://doi.org/10.1007/s10585-021-10123-wCrossRefPubMed

11.

Buechler MB, Pradhan RN, Krishnamurty AT, Cox C, Calviello AK, Wang AW, Yang YA, Tam L, Caothien R, Roose-Girma M, Modrusan Z, Arron JR, Bourgon R, Muller S, Turley SJ (2021) Cross-tissue organization of the fibroblast lineage. Nature 593(7860):575–579. https://doi.org/10.1038/s41586-021-03549-5ADSCrossRefPubMed

12.

du Bois H, Heim TA, Lund AW (2021) Tumor-draining lymph nodes: At the crossroads of metastasis and immunity. Sci Immunol 6(63):eabg3551. https://doi.org/10.1126/sciimmunol.abg3551CrossRefPubMedPubMedCentral

13.

McGinnis CS, Miao Z, Reticker-Flynn NE, Winker J, Satpathy AT (2023) The temporal progression of immune remodeling during metastasis. bioRxiv. https://doi.org/10.1101/2023.05.04.539153CrossRefPubMedPubMedCentral

14.

Halsted W (1907) The results of radical operations for the cure of cancer of the breast. Trans Am Surg Assoc 25:61–79

15.

Pereira ER, Kedrin D, Seano G, Gautier O, Meijer EFJ, Jones D, Chin SM, Kitahara S, Bouta EM, Chang J, Beech E, Jeong HS, Carroll MC, Taghian AG, Padera TP (2018) Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science 359(6382):1403–7. https://doi.org/10.1126/science.aal3622ADSCrossRefPubMedPubMedCentral

16.

Brown M, Assen FP, Leithner A, Abe J, Schachner H, Asfour G, Bago-Horvath Z, Stein JV, Uhrin P, Sixt M, Kerjaschki D (2018) Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice. Science 359(6382):1408–1411. https://doi.org/10.1126/science.aal3662ADSCrossRefPubMed

17.

Reiter JG, Hung WT, Lee IH, Nagpal S, Giunta P, Degner S, Liu G, Wassenaar ECE, Jeck WR, Taylor MS, Farahani AA, Marble HD, Knott S, Kranenburg O, Lennerz JK, Naxerova K (2020) Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases. Nat Genet 52(7):692–700. https://doi.org/10.1038/s41588-020-0633-2CrossRefPubMedPubMedCentral

18.

Reticker-Flynn NE, Zhang W, Belk JA, Basto PA, Escalante NK, Pilarowski GOW, Bejnood A, Martins MM, Kenkel JA, Linde IL, Bagchi S, Yuan R, Chang S, Spitzer MH, Carmi Y, Cheng J, Tolentino LL, Choi O, Wu N, Kong CS, Gentles AJ, Sunwoo JB, Satpathy AT, Plevritis SK, Engleman EG (2022) Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell 185(11):1924–1942. https://doi.org/10.1016/j.cell.2022.04.019CrossRefPubMedPubMedCentral

19.

DeVito NC, Plebanek MP, Theivanthiran B, Hanks BA (2019) Role of tumor-mediated dendritic cell tolerization in immune evasion. Front Immunol 10:2876. https://doi.org/10.3389/fimmu.2019.02876CrossRefPubMedPubMedCentral

20.

Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114(2):280–290. https://doi.org/10.1172/JCI21583CrossRefPubMedPubMedCentral

21.

Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3(3):483–490PubMed

22.

Bandola-Simon J, Roche PA (2019) Dysfunction of antigen processing and presentation by dendritic cells in cancer. Mol Immunol 113:31–37. https://doi.org/10.1016/j.molimm.2018.03.025CrossRefPubMed

23.

Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, Tsui J, Ruhland MK, Kersten K, Abushawish MA, Spasic M, Giurintano JP, Chan V, Daud AI, Ha P, Ye CJ, Roberts EW, Krummel MF (2019) Unleashing type-2 dendritic cells to drive protective antitumor CD4(+) T cell immunity. Cell 177(3):556–71. https://doi.org/10.1016/j.cell.2019.02.005CrossRefPubMedPubMedCentral

24.

Gray EE, Cyster JG (2012) Lymph node macrophages. J Innate Immun 4(5–6):424–436. https://doi.org/10.1159/000337007CrossRefPubMedPubMedCentral

25.

Ohnishi K, Komohara Y, Saito Y, Miyamoto Y, Watanabe M, Baba H, Takeya M (2013) CD169-positive macrophages in regional lymph nodes are associated with a favorable prognosis in patients with colorectal carcinoma. Cancer Sci 104(9):1237–1244. https://doi.org/10.1111/cas.12212CrossRefPubMedPubMedCentral

26.

Tacconi C, Commerford CD, Dieterich LC, Schwager S, He Y, Ikenberg K, Friebel E, Becher B, Tugues S, Detmar M (2021) CD169(+) lymph node macrophages have protective functions in mouse breast cancer metastasis. Cell Rep 35(2):108993. https://doi.org/10.1016/j.celrep.2021.108993CrossRefPubMed

27.

Qian Y, Zhai E, Chen S, Liu Y, Ma Y, Chen J, Liu J, Qin C, Cao Q, Chen J, Cai S (2022) Single-cell RNA-seq dissecting heterogeneity of tumor cells and comprehensive dynamics in tumor microenvironment during lymph nodes metastasis in gastric cancer. Int J Cancer 151(8):1367–1381. https://doi.org/10.1002/ijc.34172CrossRefPubMed

28.

Deng L, Zhang H, Luan Y, Zhang J, Xing Q, Dong S, Wu X, Liu M, Wang S (2010) Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res 16(16):4105–4112. https://doi.org/10.1158/1078-0432.CCR-10-1073CrossRefPubMed

29.

Nunez NG, Tosello Boari J, Ramos RN, Richer W, Cagnard N, Anderfuhren CD, Niborski LL, Bigot J, Meseure D, De La Rochere P, Milder M, Viel S, Loirat D, Perol L, Vincent-Salomon A, Sastre-Garau X, Burkhard B, Sedlik C, Lantz O, Amigorena S, Piaggio E (2020) Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. Nat Commun 11(1):3272. https://doi.org/10.1038/s41467-020-17046-2ADSCrossRefPubMedPubMedCentral

30.

van Krimpen A, Gerretsen VIV, Mulder E, van Gulijk M, van den Bosch TPP, von der Thusen J, Grunhagen DJ, Verhoef C, Mustafa D, Aerts JG, Stadhouders R, Dammeijer F (2022) Immune suppression in the tumor-draining lymph node corresponds with distant disease recurrence in patients with melanoma. Cancer Cell 40(8):798–799. https://doi.org/10.1016/j.ccell.2022.06.009CrossRefPubMed

31.

Rahim MK, Okholm TLH, Jones KB, McCarthy EE, Liu CC, Yee JL, Tamaki SJ, Marquez DM, Tenvooren I, Wai K, Cheung A, Davidson BR, Johri V, Samad B, O’Gorman WE, Krummel MF, van Zante A, Combes AJ, Angelo M, Fong L, Algazi AP, Ha P, Spitzer MH (2023) Dynamic CD8(+) T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell 186(6):1127–1143. https://doi.org/10.1016/j.cell.2023.02.021CrossRefPubMed

32.

Miller JS, Lanier LL (2019) Natural killer cells in cancer immunotherapy. Annu Rev Cancer Biol 3(1):77–103. https://doi.org/10.1146/annurev-cancerbio-030518-055653CrossRef

33.

Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto C, Galgani M, Matarese G, Bifulco M, Ferrone S, Colucci F, Moretta A, Karre K, Carbone E (2014) Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun 5:5639. https://doi.org/10.1038/ncomms6639ADSCrossRefPubMed

34.

Gottlieb-Vedi E, Kauppila JH, Mattsson F, Hedberg J, Johansson J, Edholm D, Lagergren P, Nilsson M, Lagergren J, group F (2023) Extent of lymphadenectomy and long-term survival in esophageal cancer. Ann Surg 277(3):429–36. https://doi.org/10.1097/SLA.0000000000005028CrossRefPubMed

35.

van der Wielen N, Daams F, Rosati R, Parise P, Weitz J, Reissfelder C, Del Val ID, Loureiro C, Parada-Gonzalez P, Pintos-Martinez E, Vallejo FM, Achirica CM, Sanchez-Pernaute A, Campos AR, Bonavina L, Asti ELG, Poza AA, Gilsanz C, Nilsson M, Lindblad M, Gisbertz SS, van Berge Henegouwen MI, Romario UF, De Pascale S, Akhtar K, Cuesta MA, van der Peet DL, Straatman J (2023) Correction: three-year survival and distribution of lymph node metastases in gastric cancer following neoadjuvant chemotherapy: results from a European randomized clinical trial. Surg Endosc. https://doi.org/10.1007/s00464-023-10336-yCrossRefPubMedPubMedCentral

36.

Manfredini B, Zirafa CC, Filosso PL, Stefani A, Romano G, Davini F, Melfi F (2023) The role of lymphadenectomy in early-stage NSCLC. Cancers 15(14):3735. https://doi.org/10.3390/cancers15143735CrossRefPubMedPubMedCentral

37.

Reticker-Flynn NE, Engleman EG (2023) Lymph nodes: at the intersection of cancer treatment and progression. Trends Cell Biol. https://doi.org/10.1016/j.tcb.2023.04.001CrossRefPubMed

38.

Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, Gherardini PF, Prestwood TR, Chabon J, Bendall SC, Fong L, Nolan GP, Engleman EG (2017) Systemic immunity is required for effective cancer immunotherapy. Cell 168(3):487–502. https://doi.org/10.1016/j.cell.2016.12.022CrossRefPubMedPubMedCentral

39.

Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R, McNamara KL, Granja JM, Sarin KY, Brown RA, Gupta RK, Curtis C, Bucktrout SL, Davis MM, Chang ALS, Chang HY (2019) Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med 25(8):1251–1259. https://doi.org/10.1038/s41591-019-0522-3CrossRefPubMedPubMedCentral

40.

Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, van Hall T, Ossendorp F (2018) Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight 3(23):124507. https://doi.org/10.1172/jci.insight.124507CrossRefPubMed

41.

Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, van Nimwegen M, Lau SP, Latupeirissa K, Schetters S, van Kooyk Y, Boon L, Moyaart A, Mueller YM, Katsikis PD, Eggermont AM, Vroman H, Stadhouders R, Hendriks RW, Thusen JV, Grunhagen DJ, Verhoef C, van Hall T, Aerts JG (2020) The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell 38(5):685–700. https://doi.org/10.1016/j.ccell.2020.09.001CrossRefPubMed

42.

Saddawi-Konefka R, O’Farrell A, Faraji F, Clubb L, Allevato MM, Jensen SM, Yung BS, Wang Z, Wu VH, Anang NA, Msari RA, Schokrpur S, Pietryga IF, Molinolo AA, Mesirov JP, Simon AB, Fox BA, Bui JD, Sharabi A, Cohen EEW, Califano JA, Gutkind JS (2022) Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC. Nat Commun 13(1):4298. https://doi.org/10.1038/s41467-022-31941-wADSCrossRefPubMedPubMedCentral

43.

Darragh LB, Gadwa J, Pham TT, Van Court B, Neupert B, Olimpo NA, Nguyen K, Nguyen D, Knitz MW, Hoen M, Corbo S, Joshi M, Zhuang Y, Amann M, Wang XJ, Dow S, Kedl RM, Samedi V, Boss MK, Karam SD (2022) Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat Commun 13(1):7015. https://doi.org/10.1038/s41467-022-34676-wADSCrossRefPubMedPubMedCentral

44.

Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA Jr (2022) PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 386(25):2363–2376. https://doi.org/10.1056/NEJMoa2201445CrossRefPubMedPubMedCentral

45.

Versluis JM, Long GV, Blank CU (2020) Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med 26(4):475–484. https://doi.org/10.1038/s41591-020-0829-0CrossRefPubMed

46.

Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A (2023) Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 388(9):813–823. https://doi.org/10.1056/NEJMoa2211437CrossRefPubMedPubMedCentral

47.

Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautes-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA (2020) B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549–555. https://doi.org/10.1038/s41586-019-1922-8ADSCrossRefPubMedPubMedCentral

48.

Meylan M, Petitprez F, Becht E, Bougouin A, Pupier G, Calvez A, Giglioli I, Verkarre V, Lacroix G, Verneau J, Sun CM, Laurent-Puig P, Vano YA, Elaidi R, Mejean A, Sanchez-Salas R, Barret E, Cathelineau X, Oudard S, Reynaud CA, de Reynies A, Sautes-Fridman C, Fridman WH (2022) Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55(3):527–541. https://doi.org/10.1016/j.immuni.2022.02.001CrossRefPubMed

49.

Xia H, Zhang W, Zhang Y, Shang X, Liu Y, Wang X (2022) Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: a systematic review and meta-analysis. Front Oncol 12:978069. https://doi.org/10.3389/fonc.2022.978069CrossRefPubMedPubMedCentral

50.

Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, Chopra Z, El Naqa I, Zhou J, Bian Y, Jiang L, Tezel A, Skvarce J, Achar RK, Sitto M, Rosen BS, Su F, Narayanan SP, Cao X, Wei S, Szeliga W, Vatan L, Mayo C, Morgan MA, Schonewolf CA, Cuneo K, Kryczek I, Ma VT, Lao CD, Lawrence TS, Ramnath N, Wen F, Chinnaiyan AM, Cieslik M, Alva A, Zou W (2021) Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 27(1):152–64. https://doi.org/10.1038/s41591-020-1131-xCrossRefPubMedPubMedCentral

51.

Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA (2020) Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol 5(52):aba0759. https://doi.org/10.1126/sciimmunol.aba0759CrossRef

52.

Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, Issa A, Hugues S, Swartz MA (2012) VEGF-C promotes immune tolerance in B16 melanomas and cross-presentation of tumor antigen by lymph node lymphatics. Cell Rep 1(3):191–199. https://doi.org/10.1016/j.celrep.2012.01.005CrossRefPubMed

53.

Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S, Gajewski TF, Alitalo K, Eikesdal HP, Wiig H, Swartz MA (2016) Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest 126(9):3389–3402. https://doi.org/10.1172/JCI79434CrossRefPubMedPubMedCentral

54.

Yu X, Dai Y, Zhao Y, Qi S, Liu L, Lu L, Luo Q, Zhang Z (2020) Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. Nat Commun 11(1):1110. https://doi.org/10.1038/s41467-020-14906-9ADSCrossRefPubMedPubMedCentral

55.

Najibi AJ, Mooney DJ (2020) Cell and tissue engineering in lymph nodes for cancer immunotherapy. Adv Drug Deliv Rev 161–162:42–62. https://doi.org/10.1016/j.addr.2020.07.023CrossRefPubMedPubMedCentral

56.

Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA (2018) Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma. J Clin Oncol 36(10):942–950. https://doi.org/10.1200/JCO.2017.77.3994CrossRefPubMedPubMedCentral

57.

Zhou M, Bui N, Lohman M, van de Rjin M, Hwang G, Ganjoo K (2021) Long-term remission with ipilimumab/nivolumab in two patients with different soft tissue sarcoma subtypes and no PD-L1 expression. Case Rep Oncol 14(1):459–465. https://doi.org/10.1159/000512828CrossRefPubMedPubMedCentral

58.

Alves AM, Paredes J, Schmitt F (2019) Expression of PD-L1 in primary breast carcinoma and lymph node metastases. Surg Exp Pathol 2(1):7. https://doi.org/10.1186/s42047-019-0033-zCrossRef

59.

Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L (2020) Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. J Immunother Cancer. https://doi.org/10.1136/jitc-2020-001558CrossRefPubMedPubMedCentral

60.

Li M, Li A, Zhou S, Xu Y, Xiao Y, Bi R, Yang W (2018) Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer. BMC Cancer 18(1):4. https://doi.org/10.1186/s12885-017-3916-yCrossRefPubMedPubMedCentral

61.

Schmid P, Dent R, O’Shaughnessy J (2020) Pembrolizumab for early triple-negative breast cancer. Reply N Engl J Med 382(26):e108. https://doi.org/10.1056/NEJMc2006684CrossRefPubMed

62.

Andre T, Tougeron D, Piessen G, de la Fouchardiere C, Louvet C, Adenis A, Jary M, Tournigand C, Aparicio T, Desrame J, Lievre A, Garcia-Larnicol ML, Pudlarz T, Cohen R, Memmi S, Vernerey D, Henriques J, Lefevre JH, Svrcek M (2023) Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol 41(2):255–265. https://doi.org/10.1200/JCO.22.00686CrossRefPubMed

63.

Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodriguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD, Investigators K (2023) Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa2302983CrossRefPubMed

64.

Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, López Vivanco G, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benítez R, de la Aguado Rosa C, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, Romero A (2023) Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer. N Engl J Med 389(6):504–13. https://doi.org/10.1056/NEJMoa2215530CrossRefPubMed

65.

Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsi J, Taube JM, Lim AM, Ferrarotto R, Kaufman HL, Seebach F, Lowy I, Yoo SY, Mathias M, Fenech K, Han H, Fury MG, Rischin D (2022) Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med 387(17):1557–1568. https://doi.org/10.1056/NEJMoa2209813CrossRefPubMedPubMedCentral

66.

Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O’Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM (2019) Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 25(3):477–486. https://doi.org/10.1038/s41591-018-0337-7CrossRefPubMedPubMedCentral

Title: Interrogating the roles of lymph node metastasis in systemic immune surveillance
Authors: Pamela A. Basto
Nathan E. Reticker-Flynn
Publication date: 05-02-2024
Publisher: Springer Netherlands
Keywords: Metastasis
Lymphadenectomy
Published in: Clinical & Experimental Metastasis
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-023-10261-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer